Related Experiment Video
Updated: Nov 14, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma
Vito Vanella1, Lucia Festino1, Maria Grazia Vitale1
1Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Introduction:
Increased understanding of the interactive mechanisms between tumors and the immune system led to the development of immune checkpoint inhibitors, which have revolutioned the treatment of metastatic melanoma and subsequently many other tumors. In 2014, nivolumab and pembrolizumab, two checkpoint inhibitors binding to PD-1, were approved for the treatment of metastatic melanoma. Since then, a plethora of new molecules have enriched the armamentarium against melanoma.
Areas Covered:
This review summarizes the last updates about treatment with nivolumab and pembrolizumab, data on other PD-1/PDL-1 agents such as spartalizumab and atezolizumab and emerging compounds, new combinations with NKTR-214, anti LAG-3, anti IDO-1 and TVEC, new checkpoint inhibitors (e.g. TIM-3 or TIGIT) and other new molecules for the treatment of metastatic melanoma.
Expert Opinion:
Currently, several ongoing clinical trials are investigating novel molecules, or immunotherapy combinations, in order to achieve even better survival outcomes for patients, overcoming resistance mechanisms and improving toxicity profiles. The challenge in the near future will be to select the most appropriate treatments according to the specific characteristics of the patients.
Insights
Immune checkpoint inhibitors like nivolumab and pembrolizumab have transformed metastatic melanoma treatment. Ongoing research explores new agents and combinations to improve patient survival and reduce toxicity.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, particularly for metastatic melanoma.
- PD-1 inhibitors (nivolumab, pembrolizumab) were approved in 2014, significantly impacting treatment options.
- The understanding of tumor-immune system interactions drives the development of novel melanoma therapies.
Purpose of the Study:
- To review recent advancements in metastatic melanoma treatment using immunotherapy.
- To summarize data on PD-1/PD-L1 agents, combination therapies, and emerging checkpoint inhibitors.
- To highlight ongoing clinical trials and future challenges in personalized melanoma treatment.
Main Methods:
- Review of current literature on metastatic melanoma immunotherapy.
- Analysis of clinical trial data for novel agents and combinations.
- Synthesis of expert opinions on future therapeutic strategies.
Main Results:
- Nivolumab and pembrolizumab are established treatments for metastatic melanoma.
- New agents like spartalizumab and atezolizumab, along with combinations (e.g., NKTR-214, anti-LAG-3, anti-IDO-1, TVEC), are under investigation.
- Emerging checkpoint inhibitors targeting TIM-3 and TIGIT show promise.
Conclusions:
- Continuous research aims to enhance survival outcomes and overcome resistance in metastatic melanoma.
- Optimizing treatment selection based on patient-specific characteristics is crucial for future success.
- Improving toxicity profiles of immunotherapies remains a key objective.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy